Current Evidence-Based Practices for Menopausal Symptoms

Yıl 2022, , 1609 - 1618, 22.12.2022

Burcu Öskan Fırat , Ergül Aslan

https://doi.org/10.37989/gumussagbil.943087

Öz

The aim of this review is to ensure that nurses, who provide counseling and care to women during menopause, deliver care with a holistic approach, in the light of evidence-based practices, and to examine current recommendations in accordance with the literature. Menopause is defined as the permanent end of the menstrual period due to loss of ovarian function. This physiological process, which is the last stage of the reproductive age, causes women to experience both physical and emotional problems and negatively affects their quality of life. At the beginning of the premenopausal period, as a result of the reduction of ovarian function, early symptoms such as menstrual irregularities, decrease in fertility, vasomotor symptoms, sexual dysfunction, sleep disorders, headaches, mood swings arise, while osteoporosis and cardiovascular diseases emerge in the later period. There are many evidence-based practices in the management of these symptoms during menopause. Said practices are thorough questioning of menopause symptoms, hormone therapy, non-hormonal pharmacological agents, regular exercise, yoga and relaxation exercises, keeping body mass index in a normal range, avoiding smoking, applications that will lower the body temperature, vitamin D supplement and training and consulting services for menopause symptoms.

Anahtar Kelimeler

Nursing care, Evidence-Based practices, Menopause

Menopoz Semptomlarına Özgü Güncel Kanıt Temelli Uygulamalar

Öz

Bu derlemenin amacı menopoz döneminde kadınlara danışmanlık ve bakım veren hemşirelerin bütüncül yaklaşımla, kanıt temelli uygulamalar ışığında bakım sunmalarını sağlamak ve güncel önerileri literatür doğrultusunda incelemektir. Menopoz over fonksiyonlarının kaybı nedeniyle menstrüel periyodun kalıcı olarak sona ermesi olarak tanımlanmaktadır. Üreme çağının son evresi olan bu fizyolojik süreç kadınların hem fiziksel hem de duygusal sorunlar yaşamalarına neden olarak yaşam kalitelerini olumsuz etkilemektedir. Premenopozal dönemin başında over fonksiyonlarının azalmasına bağlı olarak adet düzensizlikleri, doğurganlıkta azalma, vazomotor semptomlar, cinsel işlev bozukluğu, uyku bozuklukları, baş ağrısı, ruh hali değişiklikleri gibi erken dönem semptomları ortaya çıkarken, osteoporoz ve kardiyovasküler hastalıklar ise geç dönemde ortaya çıkmaktadır. Menopoz döneminde yaşanan bu semptomların yönetiminde birçok kanıt temelli uygulama mevcuttur. Bu uygulamaların başında menopoz semptomlarının kapsamlı şekilde sorgulanması, hormon tedavisi, hormonal olmayan farmakolojik ajanlar, düzenli egzersiz, yoga ve gevşeme egzersizleri, beden kitle indeksini normal sınırlarda tutma, sigara içmekten kaçınma, vücut sıcaklığını düşürecek uygulamalar, D vitamini desteği, menopoz semptomlarına yönelik eğitim ve danışmanlık hizmetleri yer almaktadır.

Anahtar Kelimeler

Hemşirelik bakımı, kanıt temelli uygulamalar, menopoz

Kaynakça

• 1. Cramer, H, Lauche, R, Langhorst, J. and Dobos, G. (2012). “Effectiveness of Yoga for Menopausal Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”. Evidence-Based Complementary and Alternative Medicine, Article ID 863905, 1-11.
• 2. Lay, A.N.R, Nascimento, C.F, Horta B.L. and Filho A.D.P.C. (2020). “Reproductive Factors and Age at Natural Menopause: A Systematic Review and Meta-Analysis”. Maturitas, 131, 57–64.
• 3. International Menopause Society, 2020. https://www.imsociety.org/menopause_terminology.php?SESSID=vol4je0o9cfvkibcjnv9lo6467#:~:text=phase%20of%20life.,Definitions,loss%20of%20ovarian%20follicular%20activity. (Erişim Tarihi: 06.09.2020).
• 4. Zhu, D, Chung, H.F, Pandeya, N, Dobson, A. J, Kuh, D, Crawford, S. L. and Mishra, G.D. (2018). “Body Mass Index and Age at Natural Menopause: An International Pooled Analysis of 11 Prospective Studies”. European Journal of Epidemiology, 33 (8), 699–710.
• 5. The National Institute for Health and Care Excellence (2015). “Menopause: Diagnosis And Management”. NICE guideline. https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-pdf-1837330217413 (Erişim Tarihi: 01.09.2020).
• 6. Ibrahim, Z.M, Ghoneim, H.M, Madny, E.H, Kishk, E.A, Lotfy, M, Bahaa, A. and Mohamed, A. S. I. (2020). “The Effect of Menopausal Symptoms on The Quality of Life Among Postmenopausal Egyptian Women”. Climacteric, 23 (1), 9-16.
• 7. Ahuja M. (2016). “Age of Menopause and Determinants of Menopause Age: A PAN India Survey by IMS”. J Mid-life Health, 7, 126-131.
• 8. İkiışık, H, Turan, G, Kutay F, Karamanlı D.C, Güven E, Özdemir E, Taşdemir, M. and Maral I. (2020). “Awareness of Menopause and Strategies to Cope with Menopausal Symptoms of The Women Aged Between 40 and 65 Who Consulted to a Tertiary Care Hospital”. ESTUDAM Public Health Journal, 5 (1), 10-21.
• 9. Sussman, M, Trocio, J, Best, C, Mirkin, S, Bushmakin, A.G, Yood, R. and Louie, M. (2015). “Prevalence of Menopausal Symptoms Among Mid-Life Women: Findings From Electronic Medical Records”. BMC Women's Health, 15 (58), 2-5.
• 10. Sharifa, S.N. and Darsareh F. (2019). “Effect of Royal Jelly on Menopausal Symptoms: A Randomized Placebo Controlled Clinical Trial”. Complementary Therapies in Clinical Practice, 37, 47-50.
• 11. Tal, J, Suh, S.A, Dowdle, C. and Nowakowski, S. (2015). “Treatment of Insomnia, Insomnia Symptoms, and Obstructive Sleep Apnea During and After Menopause: Therapeutic Approache”. Current Psychiatry Reviews, 11 (1), 63–83.
• 12. Jurgens, T, Chan, B, Caron, C. and Whelan, A.M. (2020). “A Comparative Analysis of Recommendations Provided by Clinical Practice Guideline for Use of Natural Health Products in The Treatment of Menopause related Vasomotor Symptoms”. Complementary Therapies in Medicine, 49, 10228.
• 13. Shifren, J.L. and Gass, M.L.S. (2014). “The North American Menopause Society Recommendations for Clinical Care of Midlife Women”. Menopause, 21 (10), 1038–1062.
• 14. Costanian, C, Zangiabadi, S, Bahous, S.A, Deonandan, R. and Tamim, H. (2020). “Reviewing the Evidence on Vasomotor Symptoms: The Role of Traditional and Non-Traditional Factors”. Climacteric, 23 (3), 213-223.
• 15. Sievert, L.L, Begum, K, Sharmeen, T, Murphy, L, Whitcomb B.W, Chowdhury, O, Muttukrishna, S. and Bentley, G.R. (2016). “Hot Flash Report and Measurement Among Bangladeshi Migrants, Their London Neighbors, and Their Community of Origin”. Am. J.Phys.Anthropol, 161, 620-633.
• 16. ACOG (2014). “Releases Clinical Guidelines on Management of Menopausal Symptoms”. American Family Physician, 90 (5), 1-10.
• 17. The 2017 Hormone Therapy Position Statement of The North American Menopause Society (2017). Menopause: The Journal of The North American Menopause Society, 24 (7), 728-753.
• 18. Bălan, A, Dıma, L, Varga, I, Bîgıu N.F. and Moga S. (2019).“Management Strategies of The Symptomatology and Pathology Assocıated with Menopause – an Overvıew”. Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences, 12 (61), 1-14.
• 19. Corbelli, J, Shaikh, N, Wessel, C. and Hess, R. (2015). “Low-dose Transdermal Estradiol for Vasomotor Symptoms”. Menopause, 22 (1), 114–121.
• 20. Lobo, R.A, Archer, D.F, Kagan, R, Kaunitz, A.M, Constantine, G.D, Pickar, J.H, Graham, S, Bernick, B. and Mirkin, S. (2018). “A 17b-Estradiol–Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women A Randomized Controlled Trial”. Obstet Gynecol, 132, 161–70.
• 21. Pinkerton, J.V, Joffe, H, Kazempour, K, Mekonnen, H, Bhaskar, S. and Lippman, J. (2015). “Low-dose Paroxetine (7.5 Mg) İmproves Sleep in Women with Vasomotor Symptoms Associated with Menopause”. Menopause, 22 (1), 50–58.
• 22. Pinkerton, J.V, Kagan, R, Portman, D, Sathyanarayana, R. and Sweeney, M. (2014). “Phase 3 Randomized Controlled Study of Gastroretentive Gabapentin for the Treatment of Moderate-to-Severe Hot Flashes in Menopause”. Menopause, 21 (6), 567–573.
• 23. Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society (2015). Menopause, 22 (11), 1155–1174.
• 24. Daley, A, Stokes-Lampard, H, Thomas, A. and MacArthur, C. (2014). “Exercise for Vasomotor Menopausal Symptoms”. Cochrane Database of Systematic Reviews, 28 (11), Art. No. CD006108. https://doi.org/10.1002/14651858.CD006108.pub4
• 25. Pace, D.T, Chism, L.A, Graham, S. and Amadio, J. (2020). “How Nurse Practitioners Approach Treatment of Genitourinary Syndrome of Menopause”. The Journal for Nurse Practitioners, 16, 136-142.
• 26. Gandhi, J, Chen, A, Dagur, G, Suh, Y, Smith, N, Cali, B. and Khan, S. A. (2016). “Genitourinary Syndrome of Menopause: An Overview Of Clinical Manifestations, Pathophysiology, Etiology, Evaluation, and Management”. American Journal of Obstetrics and Gynecology, 215 (6), 704–711.
• 27. Stuenkel, C.A, Davis, S.R, Gompel, A, Lumsden, M.A, Murad, M.H, Pinkerton, J.V. and Santen R.J. (2015). “Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline”. The Journal of Clinical Endocrinology & Metabolism, 100 (11), 3975–4011.
• 28. Kaunitz, A.M. and Manson, J.E. (2015). “Management of Menopausal Symptoms”. Obstet Gynecol, 126 (4), 859–876.
• 29. Paraiso, M.F.R, Ferrando, C.A, Sokol, E.R, Rardin, C.R, Matthews, C.A, Karram, M.M. and Iglesia C.B. (2020). “A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women with Genitourinary Syndrome of Menopause: The VeLVET Trial”. Menopause, 27 (1), 50-56.
• 30. Cagnacci, A, Xholli, A. and Venier, M. (2020). “Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use”. Patient Preference and Adherence, 14, 55–62.
• 31. Attarian, H, Hachul, H, Guttuso, T. and Phillips, B. (2015). “Treatment of Chronic İnsomnia Disorder in Menopause”. Menopause, 22 (6), 674–684.
• 32. Ripa, P, Ornello, R, Degan, D, Tiseo, C, Stewart, J, Carolei, A. and Sacco, S. (2015). “Migraine in Menopausal Women: A Systematic Review”. International Journal of Women’s Health, 7; 773–782.
• 33. Fu, J.X, Luo, Y, Chen, M.Z, Zhou, Y.H, Meng, Y.T, Wang, T, Qin S. and Xu, C. (2020). “Associations Among Menopausal Status, Menopausal Symptoms, and Depressive Symptoms in Midlife Women in Hunan Province, China”. Climacteric, 23 (3), 259-266.
• 34. Baber, R.J, Panay, N. and Fenton, A. (2016). “2016 IMS Recommendations on Women’s Midlife Health and Menopause Hormone Therapy”. Climacteric, 19 (2), 109–150.
• 35. Muka, T, Oliver-Williams, C, Kunutsor, S, Laven, J. S. E, Fauser, B.C.J.M, Chowdhury, R. and Franco, O.H. (2016). “Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality”. JAMA Cardiol, 1 (7), 767-776.
• 36. Dosi, R, Bhatt, N, Shah, P. and Patell, R. (2014). “Cardiovascular Disease and Menopause”. Journal of Clinical and Diagnostic Research, 8 (2), 62-64.
• 37. Jafari, F, Hadizadeh, M.H, Zabihi, R. and Ganji, K. (2014). “Comparison of Depression, Anxiety, Quality of Life, Vitality and Mental Health Between Premenopausal and Postmenopausal Women”. Climacteric, 17 (6), 660–665.
• 38. Noble, N. (2018). “Symptom Management in Women Undergoing the Menopause”. Nursing Standard, 32 (22), 53–63.